{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:24:15Z","timestamp":1775024655749,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd (Basel, Switzerland).","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab. Results: All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant (p = 0.013), whereas all perfusion parameters showed significant differences between baseline and day +42 (p = 0.003, p = 0.049, and p = 0.002, respectively). Among the 16 patients evaluable for efficacy, a significant decline in BV at day +7 from baseline was observed in tumors with no response (p = 0.0418). Conclusions: Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs.<\/jats:p>","DOI":"10.3390\/cancers13215566","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T20:41:14Z","timestamp":1636317674000},"page":"5566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-7607","authenticated-orcid":false,"given":"Francisco","family":"Aya","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain"},{"name":"Pompeu Fabra University, 08002 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Benegas","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Vi\u00f1olas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-3994","authenticated-orcid":false,"given":"Ivan","family":"Vollmer","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainara","family":"Arcocha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-7723","authenticated-orcid":false,"given":"Marcelo","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic, 08036 Barcelona, Spain"},{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/1078-0432.CCR-18-1894","article-title":"Redefining Treatment Paradigms in First-line Advanced Non\u2013Small-Cell Lung Cancer","volume":"25","author":"Heigener","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4258s","DOI":"10.1158\/1078-0432.CCR-040023","article-title":"Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer","volume":"10","author":"Sandler","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_3","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non\u2013Small-Cell Lung Cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013Carboplatin Alone or with Bevacizumab for Non\u2013Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"New Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12094-017-1795-y","article-title":"SEOM\u2013SERAM\u2013SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer","volume":"20","author":"Bolton","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2214\/AJR.08.1367","article-title":"Tumor Response in Patients With Advanced Non\u2013Small Cell Lung Cancer: Perfusion CT Evaluation of Chemotherapy and Radiation Therapy","volume":"193","author":"Wang","year":"2009","journal-title":"Am. J. Roentgenol."},{"key":"ref_9","first-page":"1","article-title":"Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC)","volume":"3","author":"Aguado","year":"2019","journal-title":"Eur. Radiol. Exp."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/JTO.0000000000000376","article-title":"Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy","volume":"10","author":"Sudarski","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s00330-010-1869-5","article-title":"Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: A new method of monitoring treatment?","volume":"20","author":"Lind","year":"2010","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1148\/radiol.2017162204","article-title":"Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups","volume":"286","author":"Yabuuchi","year":"2018","journal-title":"Radiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1148\/radiol.11100600","article-title":"Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience","volume":"259","author":"Fraioli","year":"2011","journal-title":"Radiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20120174","DOI":"10.1259\/bjr.20120174","article-title":"Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects","volume":"86","author":"Fraioli","year":"2013","journal-title":"Br. J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00330-013-2821-2","article-title":"Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy","volume":"23","author":"Tacelli","year":"2013","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000313876","article-title":"Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel?","volume":"47","author":"Michailidou","year":"2010","journal-title":"J. Vasc. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000119756","article-title":"Paclitaxel Induces Vascular Endothelial Growth Factor Expression through Reactive Oxygen Species Production","volume":"81","author":"Kim","year":"2008","journal-title":"Pharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-04-2624","article-title":"Antiangiogenic Concentrations of Paclitaxel Induce an Increase in Microtubule Dynamics in Endothelial Cells but Not in Cancer Cells","volume":"65","author":"Pasquier","year":"2005","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1148\/radiol.10100181","article-title":"Assessment of Non\u2013Small Cell Lung Cancer Perfusion: Pathologic-CT Correlation in 15 Patients","volume":"257","author":"Tacelli","year":"2010","journal-title":"Radiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/RCT.0b013e318277c84f","article-title":"Assessment of Tumor Vascularity in Lung Cancer Using Volume Perfusion CT (VPCT) With Histopathologic Comparison: A further step toward an individualized tumor characterization","volume":"37","author":"Spira","year":"2013","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JTO.0b013e31823085f4","article-title":"Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab","volume":"7","author":"Zhao","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs","volume":"21","author":"Lubberink","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1078-0432.CCR-19-1739","article-title":"Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma","volume":"26","author":"Gerstner","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1088\/1361-6560\/61\/24\/8736","article-title":"Stability of radiomic features in CT perfusion maps","volume":"61","author":"Bogowicz","year":"2016","journal-title":"Phys. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00330-018-5639-0","article-title":"Prognostic value of radiomic analysis of iodine overlay maps from dual-energy computed tomography in patients with resectable lung cancer","volume":"29","author":"Choe","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:26:50Z","timestamp":1760167610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":26,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215566"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215566","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]}}}